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The endogenous opioid system consists of approximately 
30 different opioid peptides, including β- endorphins, Met5-
enkephalin and Leu5-enkephalin, orphanin FQ (also known 
as nociceptin) and dynorphins. These opioid peptides bind 
to their cognate G protein- coupled receptors, namely, the 
μ- opioid peptide receptor (MOP; also known as MOR), 
δ- opioid peptide receptor (DOP; also known as DOR), 
κ- opioid peptide receptor (KOP; also known as KOR) and 
nociceptin opioid peptide receptor (NOP; also known 
as OPRL1). The endogenous opioids and their receptors 
are expressed by various cell types and widely distributed 
throughout the body, including the central and peripheral 
nervous systems, immune cells, the adrenal medulla and 
the gonads, with the potential to modulate many different 
physiological and psychological processes (Fig. 1). From 
the distribution of the opioid peptides throughout various 
brain regions, it is clear that the endogenous opioid system 
has functions beyond the modulation of pain perception. 
For example, in addition to their actions at the spinal cord 
and periaqueductal grey matter in modulating pain trans-
mission, enkephalins are located within the amygdala, 
where they regulate emotional responses. Their presence 
in the autonomic nuclei of the hypothalamus is important 
for the regulation of cardiovascular and/or respiratory func-
tion, and they exert broad effects on anterior (and poste-
rior) pituitary hormone secretion, including stimulating 
the release of prolactin, growth hormone and adrenocorti-
cotropic hormone and inhibiting the release of luteinizing 
hormone, oxytocin and arginine vasopressin.
The hippocampus is a key brain structure crucial in 
learning and memory, especially in contextual memory. 
The opioid peptides and their receptors are expressed 
in all hippocampal regions1–3, including the dentate 
gyrus (DG). The action of exogenous opioid drugs 
in the hippocampus is likely involved in the effects of 
opioids on learning and memory. Indeed, opioid drugs 
can impair anterograde and retrograde recall in patients 
with pain4. The other effect of opioids that is clearly 
linked to learning and memory is the development of 
addiction. Addiction and relapse have been interpreted 
as resulting from an abnormally robust memory formed 
during the opioid- taking experience5. Because the 
hippocampus is also included in the reward circuitry 
(Fig. 2), the opioid- dependent mnesic effects are also 
associated with the extensively studied positive (that is, 
pleasure) and negative (that is, stress, depression and 
anxiety related to withdrawal) affect and emotion, as well 
as the incentive salience characterizing the consump-
tion of opiates6. The role of opioids in regulating both 
memory and affect, as well as emotion, is important in 
view of the current epidemiological context of opioid 
drug addiction, which is at an all- time high in North 
America, where opioid overdose is one of the leading 
causes of death. Indeed, the concept that both affec-
tive dysregulation and learning are the driving forces 
behind addictive behaviours, where the disruption of 
consolidating the contextual memory associated with 
drug experiences and rewards may have therapeutic 
potential to prevent relapse6–8, has gained attention in 
the past decade5.
The presence of opioid sites of action in the hippo-
campus also explains the opioid modulation of neuro-
genesis, which is a phenomenon that occurs in two 
neurogenic brain regions, one of them being the DG9–16. 
Opioid
A broad term used to 
designate all substances, 
natural (for example, morphine) 
and synthetic (for example, 
fentanyl), that bind to opioid 
receptors in the nervous 
system.
Hippocampus
A major anatomical structure 
located in the medial temporal 
lobe of the mammalian brain 
that processes a unidirectional 
flow of information via a 
trisynaptic loop.
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Abstract | Mortality due to opioid use has grown to the point where, for the first time in history , 
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Adult neurogenesis refers to the generation of new 
neurons in adult brain17 (Fig. 3a), and it has been widely 
recognized to influence cognitive processes18 such as 
affect, mood, emotion19–21, learning and memory22,23. 
Activity of the new neurons selectively integrated into 
existing circuitry can be influenced by animal expe-
riences24 and may modify the hippocampal synaptic 
plasticity involved in learning and memory (that is, 
long- term potentiation (LTP))25. Thus, neurogene-
sis presents itself as a common mechanism through 
which opioids can alter affect, mood, emotion, learn-
ing and memory. Targeting neurogenesis in adults will 
provide new perspectives for the development of anti- 
addiction therapies. The other non- nociceptive opioid 
effects, such as respiratory depression, have not been 
correlated to learning and memory, affect and emo-
tion, or neurogenesis to our knowledge. This Review 
highlights how opioid drugs can modulate adult neu-
rogenesis in order to change learning and affect (that 
is, anxiety and depression). The term ‘opioids’ is often 
used instead of ‘opiates’ because of the difficulty in 
distinguishing between the direct effect of opiates on 
biological processes and the opiate- dysregulated endog-
enous opioid system, which in turn can regulate the 
same processes.
Opioid effects on neurogenesis
Many reports describe the opioid- receptor-mediated 
regulation of neurogenesis17 in both the embryonic 
and adult brain, along with in vitro studies using neu-
ral stem and progenitor cells (NSPCs) extracted from 
the brains of mice and rats. The results suggest the 
universal modulation by opioids of both embryonic 
and adult neurogenesis in a variety of brain sites. The 
difference between exogenous and endogenous opi-
oids is noteworthy, because the modulatory effects 
of endogenous opioids are considered physiological, 
while the addictive effects of exogenous opioids, which 
are the primary focus of this Review, represent the 
pathological status.
Neural progenitor proliferation. Although the majority 
of NSPCs in the CNS undergo differentiation and finally 
lose their capacity to divide, actively dividing cells in 
both embryonic and adult brains have nonetheless been 
observed. As an indispensable process in the mainte-
nance of the stem pool and the generation of functional 
differentiated cells17,26,27, the proliferation of NSPCs is a 
crucial step in the regulation of neurogenesis (Fig. 3a). 
Thus far, the regulation of NSPC proliferation is con-
sistently observed in response to many factors, including 
MOP- targeting opioid drugs17.
The antiproliferative effects of opioids on embryonic 
NSPC proliferation were shown in the dorsal telenceph-
alon of the E15.5 embryonic mouse. Acute in utero mor-
phine treatment resulted in a prolonged g2/M phase in 
both radial glial and basal progenitor cells, suggesting 
a role of morphine in inhibiting cell cycle progression 
and embryonic neurogenesis in the developing cor-
tex28. More recently, it was found that acute morphine 
exposure inhibited the proliferation of NSPCs sepa-
rated from cortices of E14 mice, which was reversed by 
the addition of naloxone, a non- selective antagonist of 
opioid receptors29. Similar results were discovered in 
NSPCs isolated from embryonic rat telencephalon, as 
chronic morphine treatment inhibited the proliferation 
rate of NSPCs in a concentration- dependent manner, 
and opioid receptor involvement was confirmed by a 
naloxone blockade.
The modulating effect of the opioid system on 
adult NSPC proliferation has been widely shown. 
This effect was first discovered by the labelling of 
5- bromo-2′- deoxyuridine (BrdU)-positive cells in the DG 
of adult rats, which indicated an antiproliferative effect 
of both morphine and heroin9. Similarly, the cell cycle 
modulation of NSPCs in the adult mouse subgranular 
zone (SGZ) by morphine was further supported by 
using two endogenous cell cycle markers, proliferating 
cell nuclear antigen (PCNA) and phosphorylated histone 
H3 (pHisH3), along with BrdU labelling10. The impaired 
NSPC proliferation in adult animals was shown to be 
reversible, and drug withdrawal resulted in a rebound 
increase in proliferating cells, which was rescued to the 
normal level after 2 weeks of withdrawal11.
There are two noteworthy aspects of adult NSPC 
proliferation inhibition by morphine. First, the admin-
istration paradigm determines the effect of modulating 
NSPC proliferation. For example, pellet implantation, 
which produces a high and stable morphine concentra-
tion in the blood, resulted in a significant decrease in 
NSPC proliferation, whereas intermittent, single daily 
morphine injections had no significant effect13. Second, 
morphine modifies adult NSPC proliferation in a stage- 
specific manner14. For example, chronic morphine 
inhibited the proliferation of type 2b and type 3 NSPCs 
rather than cells of other stages30. The results above sup-
port the antiproliferative effect of MOP- targeting opioid 
receptor agonists in both embryonic and adult NSPCs. 
In human fetal brain- derived NSPCs, a robust expres-
sion of KOP was observed and, in contrast to morphine, 
κ- agonists such as U50,488 and dynorphin 1–17 stim-
ulated the proliferation and migration of these cells31. 
The effect of endogenous dynorphin remains unclear. 
Learning
The process by which we 
integrate sensory information 
from our interaction with our 
environment for behavioural 
adaptation.
Memory
The record left by a learning 
process.
Affect
A broad range of feelings that 
people can experience, 
embodying both emotions and 
moods.
Emotion
An intense feeling that is short 
term and is typically directed at 
a source, often with facial 
expressions and body language.
Opiates
The natural alkaloid 
compounds found in the  
opium poppy plant Papaver 
somniferum.
Neurogenic brain regions
in the adult mammal, these 
include the subgranular zone  
of the dentate gyrus in  
the hippocampus and the 
subventricular zone–oflactory
bulb system.
Mood
A less specific and less intense 
state of mind than emotion 
that is less likely to be 
provoked by a particular event 
but lasts longer.
G2/M phase
A period of protein synthesis 
and rapid cell growth (g2) 
transitioning into division (M).
Fig. 1 | opioid actions throughout the body. a | The human body naturally synthetizes 
opioids, which are used as neurotransmitters to regulate many vital functions. 
Endogenous and exogenous opioids act through receptors found peripherally on 
nerve terminals innervating the adrenal glands, pancreas and gastrointestinal tract 
and on immune, epidermal and dermal cells140,141, thus modulating steroid production, 
body weight via insulin secretion, opioid- induced constipation, inflammation and 
wound healing140,142–145. b | Opioids also activate centrally located receptors, such as 
the µ- opioid peptide receptor (MOP), that play a variety of roles in brain function. 
Control of food and drug intake is regulated by MOP in the prefrontal cortex (PFC) (1); 
analgesia, slow breathing and relaxation can be induced by the activation of MOP in 
the anterior cingulate, thalamus, brainstem nuclei, spinal cord and dorsal root ganglia 
(2); sensory perception can be influenced by MOP in parietal and temporal cortices (3); 
motivation, desire and associative learning involve stimulation of MOP in the nucleus 
accumbens (NAc), caudate–putamen (CPu) nuclei, ventral tegmental area (VTA) and 
substantia nigra (SN), key structures of the reward system (4); MOP is expressed in  
the amygdala (AMG), which is required for emotional conditioned learning and 
responses (5); MOP activation in the hippocampus (HIPP) can alter learning  
and neurogenesis (6); and MOP is present in both the locus coeruleus, a structure 
important in stress and drug withdrawal (7), and the cerebellum (8)2,6,61,141,146,147.  
In general, the expression of opioid peptides in projection neurons, immune cells, or 
epidermal and dermal cells overlaps with the location of opioid receptor expression, 
reflecting the autocrine, paracrine and endocrine mechanism of action of endogenous 
opioids61,140. DG, dentate gyrus.
◀
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The data point to differential effects of targeting different 
opioid receptor types.
NSPC differentiation and maturation. Differentiation 
is the process that occurs when proliferating NSPCs give 
rise to offspring with different lineages and phenotypes. 
Regarding neurogenesis, neuronal differentiation of 
NSPCs and the following maturation of neuroblasts are 
crucial steps in determining the rate of newborn neuron 
generation32. The initiation of differentiation and line-
age determination occurs at a stage as early as that of 
type 2 cells that feature limited self- renewal and tran-
sient amplification33, which is therefore a crucial stage in 
the study of neurogenesis modulated by opioids.
It was reported that enkephalin and U69,593, ago-
nists of MOP and KOP, respectively, promoted the 
differentiation of embryonic stem cells (ESCs) to 
neuronal- oriented precursors via the activation of 
extracellular- signal-regulated kinase (ERK)34. However, 
both opioid agonists inhibited NSPC- derived neuro-
genesis and astrogenesis via their corresponding recep-
tors by means of p38-mediated and ERK- mediated 
pathways, respectively35. This report was supported 
by a recent in vitro study, as neuronal differentiation 
of primary embryonic NSPCs was inhibited by mor-
phine sulfate at both early and late stages of cellular 
differentiation, implicating the role of opioids in fetal 
brain development36. Findings from studies using neu-
ral ESCs support the role of the third type of opioid 
receptor, DOP, in embryonic neurogenesis and neuro-
protection, as its selective agonist SNC80 could 
promote neural differentiation through the activation 
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Fig. 2 | Neural pathways involved in opioid- mediated mnesic changes. Aberrant neuroadaptations in three associative 
memory systems have been described to contribute to drug addiction6. These systems include conditioned- incentive 
learning supported by the nucleus accumbens (NAc) and amygdala (AMG); habit learning depending on the caudate–
putamen (CPu); and declarative and contextual memory encoded by the hippocampus (HIPP)6. The NAc, AMG and CPu are 
also key components of the reward–salience–emotion circuit. The centrally localized NAc processes context and cue 
information from the HIPP — probably conveyed by glutamatergic projections — and is associated with the reinforcing 
effects of opioids, reflected by increased dopaminergic transmission from the ventral tegmental area (VTA). Opioids 
facilitate dopamine release in the NAc both directly and indirectly by inhibiting GABAergic control over the dopaminergic 
neurons in the VTA148. The opioid system influences the memory systems via enkephalinergic projections into the HIPP, 
NAc, AMG and VTA and via dynorphin projections into the NAc and/or AMG2,6,146. Additionally , the NAc integrates 
glutamatergic inputs from the basolateral amygdala (BL A), which encodes the environmental affective value during a drug 
experience. After long- term opioid exposure, the summed information resulting from the convergence of all these 
afferences131 exits the NAc and is converted into the behaviour of opioid dependence or relapse to opioid seeking via 
enhanced extrapyramidal motor system activity133,148. Decreased GABAergic control of the motor system from the NAc 
and imbalance in neurotransmission in and from the prefrontal cortex (PFC) are hypothesized to contribute to the loss of 
inhibitory control and poor decision- making, leading to drug- induced reinstatement6,148. Opiate- withdrawal-related 
memory , reflected by enhanced hippocampal plasticity during opiate withdrawal, can also facilitate relapse5. DG, dentate 
gyrus; SN, substantia nigra. Adapted from reF.149, CC- BY-2.0 (https://creativecommons.org/licenses/by/2.0/uk/).
Cell cycle
A series of consecutive phases 
— gap 1 (g1) phase, DNA 
synthesis (S) phase, gap 2 (g2) 
phase (growth) and mitosis or 
meiosis (M) phase — that lead 
to the duplication and division 
of genetic information into two 
daughter cells.
5-bromo-2′-deoxyuridine
(BrdU). A synthetic analogue of 
thymidine and marker of 
proliferating cells.
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of Trk- dependent tyrosine kinase, along with the asso-
ciation of PI3K, PKC, CaMKII and MEK37. Moreover, 
buprenorphine, a partial agonist of MOP and antago-
nist of DOP and KOP, was found to decrease the pro-
liferation and differentiation of cultured rat embryonic 
NSPCs by inhibiting brain- derived neurotrophic factor 
(BDNF) expression38. The effects of opioids on NSPC 
differentiation may rely on the administration para-
digm, the targeted opioid receptors and the origins of 
embryonic NSPCs.
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Fig. 3 | Neurogenesis and biased MoP agonism in NsPc proliferation 
and differentiation. a | The subgranular zone (SGZ) of the dentate gyrus 
(DG) provides a unique microenvironment where adult neural stem and 
progenitor cells (NSPCs) undergo several consecutive developmental 
stages characterized by different cell types17. NSPCs are derived from 
embryonic stem cells that survived in the adult SGZ. NSPCs self- renew and 
include type 1 radial- glia-like (RGL) stem cells, which give rise to 
intermediate progenitor cells type 2a and 2b. These type 2 cells can 
generate type 3 progenitors (neuroblasts), which are capable of 
differentiating into immature neurons. During maturation, immature 
neurons become granule neurons and are functionally integrated into 
the DG pre- existing circuit. Type 2b and type 3 cells, immature and mature 
neurons, express the transcription factors NeuroD1 and Prox1, which 
are specific to granule cell development32. Notch 1 promotes astroglial but 
not neuronal differentiation17. b | µ- Opioid peptide receptor (MOP) agonists 
(such as morphine) inhibit NSPC proliferation mainly by slowing the cell 
cycle G2/M phase transition (prolonged S phase) in mouse embryonic 
NSPCs28, though details regarding the mechanism remain elusive. Other 
pathways leading to stagnating proliferation (indicated by the dashed 
arrow and question mark) might exist. Morphine induces extracellular- 
signal-regulated kinase (ERK) phosphorylation in a PKCε- dependent 
manner, and the activated ERK in turn phosphorylates TRBP, which is a 
stabilizer of Dicer, the essential enzyme for microRNA maturation43. The 
mature miR-181a-5p then inhibits the transcription factor Prox1, an 
inhibitor of another transcription factor, Notch1. Thus, increased Notch1 
expression mediates the inhibition of neuronal differentiation15. The 
inhibition of neurogenic differentiation 1 (NeuroD1) phosphorylation is 
another pathway by which morphine affects the transition of NSPCs into 
immature neurons in adult mice16. It is inferred that although both morphine 
and fentanyl affect NeuroD1 phosphorylation by inhibiting CaMKIIα, 
a crucial enzyme that catalyses NeuroD1 phosphorylation, fentanyl was 
able to activate NeuroD1 via the β- arrestin–ERK–miR-190 pathway , thus 
reflecting the biased antagonism of MOP agonists44. Involvement of this 
pathway has been demonstrated only in cultured primary neurons74.
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The role of opioids in the differentiation of adult 
NSPCs and the maturation of new neurons and glia 
has been clearly demonstrated by recent studies. The 
phenotypes of DG granule cells were shown to be sub-
stantially altered by repeated morphine administration, 
and a marked rebound was detected after 1 week of 
withdrawal, suggesting that morphine inhibits the neu-
ronal differentiation of DG granule cells11. Moreover, it 
was found that chronic morphine administration pre-
vented neuronal maturation by increasing the percent-
age of type 2b NSPCs while decreasing that of type 3 
cells31. By contrast, in vitro experiments showed that 
MOP and DOP antagonists were capable of promoting 
neuronal differentiation while inhibiting glial differen-
tiation, supporting the involvement of opioid agonists 
in adult NSPC differentiation39. In the subventricular 
zone–olfactory bulb (SVZ–OB) system, however, it was 
found that naloxone inhibited neuronal differentiation 
induced by paced mating in female rats, indicating a role 
of endogenous opioids in facilitating, rather than inhibit-
ing, the maturation of adult- born neurons40. In a recent 
study in mice, KOP agonists were found to promote 
oligodendrocyte differentiation and myelination, with 
therapeutic implications for multiple sclerosis41. Thus, 
it is clear that the endogenous opioid system, which 
modulates neural growth and development, is mim-
icked by exogenous opioids that disrupt neurogenesis 
by  inhibiting the maturation of neurons42.
Our recent research further elucidated the effects of 
opioids on the differentiation and maturation of adult 
NSPCs. Although morphine and fentanyl are both 
agonists of MOP, only morphine can modulate NSPC 
differentiation by inducing astrocyte- preferential dif-
ferentiation. This ability of morphine to control mech-
anisms of cell fate determination is attributed to its 
regulation of the miR-181a‒Prox1‒Notch1 pathway, 
which is a result of different signalling mechanisms of 
the two agonists leading to MAPK activation15 (Fig. 3b). 
Furthermore, the effect of morphine is due to its ability 
in activating the PKCε–TRBP–Dicer pathway, which 
modulates the processing of microRNA maturation43. 
Fentanyl, however, activates ERK via a β- arrestin- 
dependent pathway, thus resulting in decreased expres-
sion of miR-190, which targets and inhibits neuro-
genic differentiation 1 (NeuroD1), a transcriptional 
factor implicated in neuronal differentiation and mat-
uration44 (Fig. 3b). NeuroD1 also participates in opioid- 
mediated neurogenesis, as its overexpression rescues 
the morphine- induced loss of late- stage progenitors 
and immature neurons16. These studies reveal the com-
plexity of mechanisms that control NSPC differentiation 
and exemplify the mechanism of biased agonism in the 
 regulation of adult neurogenesis by opioids.
The findings discussed above indicate several crit-
ical signalling cascades that are responsible for the 
alterations of neurogenesis induced by opioids. These 
cascades include MAPKs and other signalling cascades 
of transcriptional factors, such as the Pax6‒Ngn2‒
Tbr2‒NeuroD1‒Tbr1 and Prox1‒Notch1 signalling 
pathways17. More recently, it was discovered that the 
regulator of G protein signalling 4 (RGS4) could regu-
late STAT5B- directed responses, which in turn modulate 
opioid- induced neurite outgrowth and neuronal differ-
entiation45. These signalling cascades, along with biased 
agonism (the ligand- dependent functional selectivity 
of a receptor for certain pathways), represent common 
mechanisms underlying opioid effects on neurogenesis.
Adult neurogenesis in humans and rodents. The role of 
adult neurogenesis disruption by long- term opioids has 
mainly been studied using addiction- related behaviours 
such as reward, opioid- associated contextual memory 
and mood changes46,47. Manipulations that increase 
adult hippocampal neurogenesis, either by environ-
mental enrichment, chronic antidepressant treatment 
or exercise, are correlated with reduced drug taking and 
relapse. Conversely, manipulations that decrease neuro-
genesis, such as stress and schizophrenia, are associated 
with increased drug taking and relapse47. Most of these 
behavioural data have been shown in rodents. However, 
the importance could be disputed because of the current 
controversy regarding whether the adult human brain, 
like the rodent brain, continues to generate new neurons. 
Indeed, a study published in March 2018 by Sorrells 
et al.48 concluded that neurogenesis in the hippocampus 
decreases throughout childhood and stops in the adult 
(after adolescence). Research on neurogenesis- regulated 
processes with animals would be useless for medical 
advances if the adult human brain could not make new 
neurons. However, a more recent report from April 2018 
by Boldrini et al.49 showed the contrary, namely, that 
neurogenesis is preserved in 79-year- old healthy adult 
humans. None of the patients presented psychiatric or 
chronic illness or drug and/or alcohol history, which, 
like their lifestyle, can influence the birth of new cells. 
The known history of the analysed post- mortem brains 
in the more recent study and the more accurate meth-
odology tend to add more validity to the persistence of 
neurogenesis throughout human ageing. Moreover, over 
the past two decades, birth dating studies in different 
brain areas using BrdU50 or 14C (reF.51) have supported 
the existence of adult human neurogenesis52. Despite the 
controversy, there is still the possibility that activities 
such as exercise and/or the administration of neurogenic 
molecules could reactivate an endogenous program of 
neurogenesis and generate new neurons in the human 
brain, as it has been demonstrated in rodents53,54 and 
monkeys55. Therefore, strategies that target neuro genesis 
to rescue opioid- dependent learning and memory 
impairments should continue to be explored.
Opioid system, learning and memory
The strong association of environmental, and possi-
bly interoceptive, cues with various hedonic aspects of 
drug experience is considered maladaptive. Indeed, this 
pathological opioid- associated memory undoubtedly 
renders abstinent patients more vulnerable to relapse 
when exposed to opioid- associated cues and/or context.
Opioid- associated memory. The reinforcing effects of 
opioids and the underlying motivational circuit charac-
terize opioid- associated learning. The opioid hedonic 
effect increases the motivation for further consumption 
by reinforcing the memories of the association between 
www.nature.com/nrn
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the opioid’s feeling of relief (negative reinforcement) 
and/or pleasure (positive reinforcement), the drug tak-
ing and the exteroceptive and interoceptive cues56. These 
opioid- associated memories are also reinforced by a neg-
ative affect following dissipation of the opioid hedonic 
effect and precipitation of physical and emotional with-
drawal, which motivate the individual to carry out com-
pulsive drug seeking6. The rewarding and/or reinforcing 
effects of opioids influence memory processes, from 
encoding and storage to retrieval (Supplementary Box 1), 
with the opioid reward circuitry sharing the same major 
neural substrates as the memory system6 (Fig. 2).
Opioid- associated learning necessitates primarily 
MOP activation, as demonstrated by the abolishment 
of morphine57,58 and heroin59 conditioned place pref-
erence (CPP) in MOP−/− mice and by the reduction of 
morphine self- administration in these mutant mice60 
(Box 1; Supplementary Table 1). DOP mediates drug- 
context learning, as indicated by impaired morphine 
CPP in DOP−/− animals61. However, DOP is involved in 
the contextual encoding but not the motivational aspect 
of a drug- associated experience because non- spatial cues 
predicting drug reward (for example, sound) restored 
morphine CPP in DOP−/− mice62. KOP activation does 
not appear to be directly involved in opioid- associated 
memory, as suggested by unchanged morphine CPP 
in KOP−/− mice63 and dynorphin knockout mice64. 
Regarding endogenous opioids, it remains unclear how 
they control maladaptive opioid- associative learning and 
memory, although dysregulation of a β- endorphin basal 
inhibitory tone may be involved in contextual- associated 
learning, as suggested by increased morphine CPP in 
β- endorphin−/− mice61,65,66 (Box 2).
During chronic morphine exposure, prepro-
enkephalin upregulation in the hippocampus67 or other 
endogenous opioids may interfere with hippocampal 
neurogenesis functioning, which potentially under-
lies opioid- associated memory16,46 (Fig. 4). Endogenous 
opioids decrease maturing neuron survival, as observed 
in MOP−/− mice12. Opiates such as morphine reduce the 
proliferation of progenitors and stimulate gliogenesis 
at the expense of neuronal differentiation15. To draw 
the mechanisms by which the modulation of neuro-
genesis could underlie the development of strong but 
maladaptive opioid- associated memories, we must 
consider neurogenesis modulation in correlation with 
every step of an opioid- associated memory task and 
during withdrawal. Indeed, neurogenesis modulation 
affects drug- associated learning processes in a time- 
dependent manner53,68. In one of the rare correlative 
studies, morphine was shown to decrease NeuroD1 
activity, possibly via inhibition of CaMKIIα, the day of 
the CPP test (day 15 — one day after the conditioning 
session)69. During that day, the mice did not receive 
a morphine injection. Thus, it is unclear whether the 
NeuroD1 decrease in activity is related to morphine 
context acquisition during training or to the beginning 
of abstinence or extinction (that is, the new associa-
tion ‘context- no morphine’). Furthermore, an absence 
of reducing effect of fentanyl on NeuroD1 activity69 
reflects a biased agonism that adds more complexity to 
the role of neurogenesis in opioid- associated learning 
and/or memory.
Chronic morphine decreases dendritic spine stabil-
ity in rodent primary hippocampal neuronal cultures 
(a downstream event modulated by NeuroD1)70–74 and 
also modulates hippocampal- dependent LTP71. LTP, 
a substrate of learning and memory, is influenced by 
neurogenesis5,25. There is confusion in interpreting 
the role of LTP in opioid- associated memory because 
there are few studies that correlate the time course of 
the LTP modulation by the opioids with each process 
of associative learning75,76. However, one of the few 
reports demonstrated that acute morphine infusion 
(1 hour) in lateral perforant path (LPP)-granule cell 
synapses of the DG attenuated LTP induction, while 
Box 1 | opioid- associated and non- opioid-associated learning and memory tasks
opioid- associated learning
associative learning in opioid and drug abuse in animals is measured by conducting either classical (Pavlovian) or operant 
(instrumental) conditioning with opioids as reinforcers132.
Classical conditioning. the conditioned place preference assesses drug (including opioid) contextual- associated memory 
and is usually utilized to examine drug reward. the animal learns to associate an environment or context (conditioned 
stimulus) with opioid taking (unconditioned stimulus). through this association, if the drug is hedonic, the animal is expected 
to spend more time in the drug- paired environment to seek the drug (conditioned response)133. if withdrawal is associated 
with the context, such as in the conditioned place aversion task, the subject will avoid spending time in that context134.
Operant (instrumental) conditioning. self- administration is the traditional model of drug abuse used to investigate the 
associative habit learning of drug taking. self- administration is based on the reinforcing property of a drug to strengthen 
the learning of a stimulus (pressing a lever) and response (drug taking) habit that will gradually become a maladaptive, 
drug- directed form of habitual behaviour135.
Non- opioid-associated (or any addictive drug) learning
Non- opioid-associated (or any addictive drug) learning refers to learning that is motivated by reinforcers other than 
opioids (or any other addictive drugs). For example, the measurement of spatial learning with the Barnes maze, radial arm 
maze, t- maze or Y- maze involves a positive reward, such as food, as an incentive to learn the area layout136. the Morris 
water maze also assesses spatial learning and relies on the water semi- aversive property to motivate learning the location 
of an escaping platform thanks to distant spatial cues136. Passive and active avoidance tests and fear conditioning are 
fear- motivated associative avoidance tasks during which subjects learn to avoid an environment by associating a cue or 
the environment itself with an aversive stimulus (for example, foot shock) previously delivered136. the novel object 
recognition task involves exploiting rodents’ innate preference for novelty to evaluate recognition memory136.
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chronic morphine infusion for 72 hours augmented 
LTP75. Similarly, hippocampal slices from morphine- 
dependent rats maintained in artificial cerebrospinal 
fluid (ACSF) with morphine (to prevent spontaneous 
withdrawal) did not express CA1 LTP. By contrast, hip-
pocampal slices from morphine- dependent rats main-
tained in ACSF with naloxone (precipitated withdrawal) 
or ACSF alone (spontaneous withdrawal) displayed 
LTP76. Therefore, the morphine- mediated enhanced 
LTP may not be involved in so- called opioid- cue asso-
ciation learning but may be the result of the dissipa-
tion of the morphine’s effects during withdrawal. This 
hypothesis of increased LTP reflecting morphine tol-
erance is supported by the fact that, unlike acute mor-
phine, endogenous opioid blockade by naloxone, CTAP 
(MOP- targeting) or nor- BNI (KOP- targeting) increases 
mossy fibre tetanus- induced LTP in wild- type rodents77. 
Moreover, morphine decreases glutamatergic transmission 
in  primary hippocampal neurons78.
Non- opioid-associated memory. In humans, opioid 
drug administration affects daily task performances 
requiring forms of memory that use reinforcers (that 
is, motivators) different from opioids4,79,80 (Box 1; 
Supplementary Box 1 and Supplementary Table 2). In 
rodents, acute and chronic morphine and/or heroin 
impairs hippocampus- dependent spatial acquisition81,82 
and retention and retrieval when injected after acquisi-
tion83. The same retention deficits were observed after 
β- endorphin, endomorphin 1 and endomorphin 2 
administration84,85. By contrast, the opioid antagonist, 
either naloxone or naltrexone, facilitates spatial acqui-
sition86 and retention87. These results suggest that 
there is an endogenous opioid basal tone that inhibits 
learning, similar to that observed in β- endorphin−/− 
mice tested for morphine- associated memory65. The 
naltrexone- mediated or naloxone- mediated improved 
learning might result from enhanced stress generated 
from the endogenous basal tone removal88. The role 
of the endogenous opioid tone inhibition in enhanc-
ing spatial learning is questioned by the behavioural 
discrepancies between the genetic backgrounds 
and mutations of knockout animals. Studies using 
MOP−/− mice with a 100% C57BL/6 background and 
MOP exon 1 excised exhibited intact acquisition 
and first retrieval86,89–91. By contrast, MOP−/− mice with 
a hybrid genetic background (that is, 50% 129SVJ and 
50% C57BL/6 or 129/Ola‒C57BL/6) or MOP exons 2 
and 3 deleted displayed impaired spatial learning57,92,93. 
These discrepancies between the different genetic 
backgrounds need to be clarified.
The aforementioned opioid- induced mnesic defi-
cits in tasks using reinforcers other than opioids may 
involve neuronal plasticity and neurogenesis modu-
lation. Less well described is the opioid- antagonist- 
mediated learning facilitation in 100% C57BL/6 mice, 
which could be of interest for the development of prom-
nesic treatments. One of the few proposed mechanisms 
suggests that chronic naltrexone increases hippo-
campal glutamatergic neurotransmission to facilitate 
learning77,86. However, studies using MOP−/− mice with 
a 129SVJ background showed, by contrast, impaired 
learning associated with attenuated LTP in the CA3 
(reF.92) and the DG94. The lower level of neurogenesis 
in the 129SVJ strain of mice compared with the 100% 
C57BL/6 mice should be taken into account when 
considering the behavioural and electrophysiological 
differences95. Again, the contradicting results linked to 
the differences between genetic backgrounds must be 
resolved. The other hypothesis relies on the fact that 
naltrexone increases the number of new neurons39,96. 
The inhibition of the MOP endogenous tone may stim-
ulate neurogenesis to positively influence long- term 
memory or even prophylactically delay or improve 
neuronal dysfunction in neurodegenerative disorders. 
No studies have assessed the effects of an opioid antag-
onist on neurogenesis in relation to both memory and 
neurodegeneration (for example, such as observed in 
dementia), but it is noteworthy that depot naltrexone 
treatment of opioid use disorder is having unanticipated 
success in reducing opioid craving97.
Treatment of maladaptive memory. Current 
treatments such as methadone replacement therapy 
or naltrexone maintenance treatment do not address 
the issue of addiction in opioid addicts, who must fol-
low these therapies throughout their lives to maintain 
permanent abstinence98. One of the strategies adopted 
by researchers to prevent relapse in patients recover-
ing from opioid dependence is to pharmacologically 
enhance cue- exposure therapy (CET). During CET, 
subjects are exposed to repeated extinction trials 
that result in cues and context previously associated 
Box 2 | Transient dysregulation of the endogenous opioid system homeostasis
Long- term opiate consumption and cessation cause transient disruption of the 
endogenous opioid system homeostasis. therefore, the organism initiates allostatic 
changes in order to re- establish the neuronal systems7,137. indeed, continuous 
circulation of exogenous opioids during chronic use overstimulates the endogenous 
opioid system. Consequently, inhibitory mechanisms take place to physiologically and 
psychologically oppose the maladaptive hedonic opioid effects and maintain 
homeostasis7,137. upon opiate removal, the compensatory actions against the 
endogenous opioid system effects become particularly important and unopposed and 
may interfere with the endogenous opioid system inhibitory control of, for example, 
aversive learning or stress, which can render abstinent patients with opiate 
dependence more susceptible to relapse.
For instance, following chronic morphine treatment in rodents, preproenkephalin 
transcription is decreased in structures responsible for reward and habit learning, such 
as the caudate–putamen (CPu) and nucleus accumbens (Nac), and increased in the 
hippocampus and cortex, both of which are involved in declarative learning and 
memory61. endogenous opioids attenuate maturing neuron survival12. Hippocampal 
preproenkephalin upregulation may interfere with neurogenesis and thus cue–drug 
association learning. under morphine withdrawal, preproenkephalin is downregulated 
in the CPu, Nac and pons, which are components of the basal ganglia, which controls 
voluntary motor movements and procedural learning61. By contrast, the dysphoric 
prodynorphin is upregulated following withdrawal from chronic intermittent  
injections in the CPu and rostral Nac61. Both enkephalin and β- endorphin inhibit the 
hypothalamic–pituitary–adrenal (HPa) axis response to stress88,138. enkephalin may also 
mediate a basal hedonic tone and basal- ganglia-mediated motor control65. therefore, 
both the preproenkephalin downregulation and prodynorphin upregulation during 
opioid abstinence and withdrawal could lead to a decrease in enkephalin’s inhibitory 
control over the HPa axis and increased anxiety, respectively88. these phenomena may 
contribute to stress- related impulsive behaviour, which in turn may impair the 
executive function, working memory and fluid intelligence observed in early abstinence 
in patients with opioid dependence79.
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with drug taking becoming associated with the lack 
of drug98–100. Drug candidates for the development of 
anti- relapse treatments combined with CET act through 
direct modulation of the neurotransmission systems. 
A partial coagonist of the glutamatergic NMDA recep-
tor, d- cycloserine, and an uncompetitive NMDA 
antagonist, memantine, are among these candidates 
and have the advantage of having been clinically 
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Fig. 4 | opioids alter normal learning by potentially regulating neurogenesis and plasticity. a | In the dentate gyrus 
(DG) of the hippocampus, opioid receptors are located in the molecular layer, the granule cell layer3,150 and the hilus150  
(not included in part a). The µ- opioid peptide receptor (MOP) is predominantly in distinct subpopulations of GABAergic 
interneurons known to inhibit granule cells: for example, the MOP is common in parvalbumin (PARV)-containing basket 
cell terminals that form inhibitory- type synapses with granule cell somata and dendrites, occurs occasionally in 
interneurons that innervate other interneurons (not represented) and appears in a modest number of hilar interneurons150. 
MOP immunoreactivity is also seen in some dendrites of granule cells150. Enkephalins are released by the lateral perforant 
path (LPP) projecting into the molecular layer150. Acute morphine infusion induces long- term potentiation (LTP) 
attenuation in LPP–granule cell synapses75. Prolonged morphine exposure and the endogenous opioid tone decrease 
dendritic spine density possibly via reduced activity of neurogenic differentiation 1 (NeuroD1) 70,71,74,151, a neurogenic 
transcription factor expressed in cells such as the immature postmitotic granule neurons. Chronic morphine treatment 
(48 hours) also stimulates clathrin- mediated endocytosis, which alters glutamate receptor trafficking73,78, thus leading to 
glutamatergic neurotransmission and LTP changes. After chronic administration (72 hours), tolerance to the effects of 
morphine enhances LTP in the same way as for opioid antagonists75. Opioid- agonist-mediated or opioid- antagonist- 
mediated LTP modulations may cause learning impairment or improvement, respectively. b | In the subgranular zone, 
opioids are assumed to directly act on neural stem and progenitor cells (NSPCs) with MOP on the cell surface39,47. 
Morphine disrupts neurogenesis by attenuating the activity of NeuroD1, which is also expressed in late- stage dividing 
type 2b and type 3 NSPCs. Reduced NeuroD1 activity is correlated with upregulation of the microRNA miR-181a (dashed 
line, potential pathway), which silences Prox1 expression. The decrease in Prox1, being an inhibitor of Notch1, results in an 
increase in the levels of Notch1, whose role is to block neuronal differentiation15, thus affecting normal learning.
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tested101,102. d- Cycloserine facilitates the extinction 
of morphine- withdrawal-associated place aversion 
in morphine- dependent rats102 and has already achieved 
positive results in CET for people with fear and anxi-
ety disorders102. Memantine was clinically effective in 
reducing physical withdrawal signs in patients with 
heroin dependence101 and attenuates the maintenance 
of morphine self- administration in mice103.
Another approach focuses on the phenomenon of 
reconsolidation occurring in parallel to learning the 
new ‘cue- no drug’ association during extinction and 
CET100,104. Reconsolidation is the process in which the for-
merly acquired cue‒drug memory becomes labile when 
reactivated or retrieved during extinction and subse-
quently restabilized into long- term storage through new 
protein synthesis after being subjected to reminders100,104. 
Treatments that interfere with reconsolidation would 
lessen the cue–drug association, its drug- seeking trigger-
ing effect and the probability of relapse. A few attempts 
to disrupt reconsolidation in opioid addiction were 
made by inhibiting ERK, protein synthesis with rapa-
mycin, muscarinic acetylcholine receptors with scopola-
mine, NMDA receptors with ketamine and β- adrenergic 
receptors with propranolol99,105. All abolished the previ-
ously learned morphine CPP when administered after 
re- exposure to a drug- paired environment. Other poten-
tial new treatments that interrupt reconsolidation, such 
as blocking PKA activity with the inhibitor Rp- cAMPs, 
were effective in attenuating cue- induced reinstatement 
in cocaine self- administration99 but need to be tested in 
opioid addiction.
An emerging anti- relapse strategy corresponds to 
the time- dependent manipulation of adult hippocam-
pal neurogenesis via a pharmacological agent. Adult 
hippocampal neurogenesis has a time- dependent 
differential effect on drug- associated memory68. Our 
recent data published in 2017 regarding a novel syn-
thetic compound, KHS101, which is known to spe-
cifically accelerate neuronal differentiation54, showed 
that KHS101 injected before morphine CPP training 
prolonged the CPP extinction whereas when adminis-
tered after morphine- induced CPP training, KHS101 
shortened extinction53. The increase in neurogenesis 
that occurs after learning a cue–drug association or that 
occurs during a period of abstinence weakens the reten-
tion of the cue–drug association and the propensity of 
relapse. Molecules such as KHS101 or surgical interven-
tions that stimulate neurogenesis such as NSPC trans-
plantation106 may have therapeutic potential in drug or 
opioid addiction. These strategies based on modulat-
ing neurogenesis have therapeutic potential, not only 
because they can weaken drug- associated memory 
and behaviour but also because of the involvement of 
neurogenesis in regulating emotional disorders such as 
depression and anxiety.
Anxiety and depression
Opioids are superior analgesics for treating moderate- 
to-severe pain because of their ability to diminish not 
only the sensory experience (pain intensity) but also 
the emotional, affective dimension (that is, how much 
it bothers the individual) pain. Thus, opioid analgesics 
have the ability to allow one to dissociate from their 
pain such that they no longer care about it, in addition 
to decreasing pain intensity. This ability of opioids to 
modulate affect transcends to mood disorders, and 
MOP agonists, at least acutely, have been recognized 
for decades to have antidepressant effects107. MOP 
agonists, with the exception of tianeptine, are not 
generally prescribed for depression108. Buprenorphine 
(a partial MOP agonist with KOP antagonist proper-
ties) is effective in alleviating symptoms of treatment- 
resistant depression109, and the KOP antagonism may 
contribute to its success in treating the negative affect 
experienced during addiction cycles. Chronic pain is 
often comorbid with mood disorders, which can range 
from 30–100% depending on the pain aetiology. This 
co- occurrence of psychopathology in patients with 
chronic pain negatively influences their pain intensity, 
pain- related disability and the effectiveness of treatment 
(Box 3). Additionally, long- term opioid use can precip-
itate depressive episodes110. We recently proposed that 
learning and memory processes are engaged in creat-
ing the association between opioid use and negative 
reinforcement (relief of negative affect, including dur-
ing withdrawal) and that this memory contributes to 
drug relapse following prolonged periods of abstinence, 
because the learned association between opioid use and 
negative reinforcement may be generalizable to differ-
ent stressors7. We surmise that in patients with chronic 
pain, the salient value associated with initial opioid use 
is pain relief, but it transitions to the alleviation of stress 
or depressed mood causative, or not, to the occurrence 
of pain. We proposed that subsequent stressors will 
trigger memories of the learned associations between 
opioid use and drug relief of dysphoric states, which 
Box 3 | risks associated with opioid misuse
risks associated with opioid misuse
•	High catastrophizing scores in chronic pain are 
associated with craving
•	Distress intolerance (the perceived or actual inability to 
manage negative emotional and somatic states)
•	Previous history of illicit drug use
•	anxiety, depression or anger
•	aberrant drug- related behaviour
•	sleep disturbance/low average number of hours of sleep
•	sex (males)
Factors that decrease opioid misuse
•	For every 1-hour increase in the average number of 
hours of nightly sleep, the risk of misuse decreased by 
20%139
Patients with chronic pain with notable 
psychopathology are more likely to report the 
following:
•	Heightened pain intensity
•	increased pain- related disability
•	More negative mood
•	reduced effectiveness of opioid analgesics compared 
with the effectiveness in patients with pain and no 
psychopathology
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could trigger drug relapse7. Many elegant studies have 
demonstrated that adult hippocampal neurogenesis 
contributes to the effectiveness of antidepressants18,111, 
and it is not unreasonable that the antidepressant 
actions of opioids and the learned association between 
opioid use and negative reinforcement may engage 
adult neurogenesis. Although most studies suggest that 
MOP agonists negatively affect or disrupt hippocampal 
neurogenesis9–11,15–17,28,29,31,35,36,43,46,112, the opposite may 
occur during cycles of withdrawal or via KOP, as KOP 
antagonists have antidepressant actions113. Furthermore, 
KOP is expressed on neural stem cells and NSPCs in 
the hippocampus, suggesting that KOP may modulate 
neurogenesis114.
The link between neuropsychiatric disorders and 
adult DG neurogenesis has been widely recognized115. 
Stress and anxiety phenotypes are associated with a 
transient reduction in neurogenesis116. Humans with 
major depressive disorder have smaller hippocampi 
and fewer mature granule cells in the DG, which may 
be a result of reduced neurogenesis117. Supporting 
this association is the observation that the ablation 
of neurogenesis gives rise to anxiety and depression- 
like behaviour in rodents118. Moreover, recent studies 
revealed the requirement of new DG neurons for anti-
depressant efficacy119,120. More direct evidence support-
ing the association between adult neurogenesis and 
mood disorders was obtained by manipulating new DG 
neurons in the absence of substantial stress, showing 
an anti- anxiety effect after the stimulation of mature 
DG neurons121.
The KOP exemplifies one of the most extensively 
studied systems involved in both mood disorders 
and adult neurogenesis107. KOP agonists and antago-
nists elicit depressive and antidepressive- like effects, 
respectively122,123. Various mechanisms and circuits 
involving monoamine transmitters have been pro-
posed to account for these phenotypes, one of which 
is the involvement of KOP in adult neurogenesis. 
Buprenorphine, an antagonist of KOP, is a negative 
modulator of NSPC proliferation112. The antidepressant 
effects of KOP antagonist nor- BNI have been proposed 
to be due partly to an increase in BDNF expression in 
the hippocampus124, which is well known to be a mecha-
nism associated with the antidepressant effects of selec-
tive serotonin reuptake inhibitors (SSRIs). The DOP 
system also regulates affective- like behaviour, where 
constitutive knockout of the DOP leads to an anxiogenic 
phenotype107. Like KOP antagonists, DOP agonists 
produce antidepressant effects in rodent models, and 
this phenotype has been associated with increases in 
BDNF expression125.
The role of the endogenous opioid system, espe-
cially the human MOP system, in depressive disorder 
has been underlined by a growing number of studies 
in recent years. For example, patients with depression 
showed MOP deactivation in the amygdala during 
social rejection, whereas healthy controls showed MOP 
activation in multiple brain regions126. This observation 
suggests the involvement of altered endogenous opioid 
activity in depression, which may help us yield novel 
therapeutics by using MOP agonists with a low risk of 
abuse127. Thus, we hypothesize the association between 
the endogenous opioid system, adult neurogenesis and 
mood and consider opioid- regulated neurogenesis 
and gliogenesis as novel targets for the treatment of 
psychiatric disorders.
Conclusion and perspectives
Knowledge of the impact of long- term opioid use on 
multiple biologic functions gives insight into how com-
plex and challenging the treatment of the adverse effects 
of opioids can be. The most effective current medical 
intervention for individuals with opioid addiction is to 
substitute short- acting, euphoric opioids (for example, 
heroin) with long half- life and partial agonists such as 
buprenorphine or methadone to keep patients in a state 
where they are prevented from experiencing the reward 
that occurs following the administration of short- acting 
opioids, as well as alleviating withdrawal128. However, 
opioid maintenance therapy is defined as a harm reduc-
tion strategy aimed at relieving the cravings and symp-
toms of withdrawal rather than the prevention of opioid 
use128. The problem of relapse remains. Long- term exog-
enous opioid use alters the communication between the 
endogenous opioid system and the circuits involved in 
learning, memory and affect and the process of neuro-
genesis. The fact that addiction involves multiple brain 
functions and their underlying circuits is important 
when considering therapy. The treatment of addiction 
cannot be undertaken by only one modality.
A novel strategy that targets simultaneously opioid- 
associated maladaptive learning and memory, mood 
alteration and opioid reward via a common mechanism 
such as neurogenesis is worth studying for its anti- 
addiction therapeutic potential. Newborn healthy cells 
have the advantage of being able to rebuild a healthy 
environment, which may help to rebalance brain chem-
istry in patients with addiction106,129 and lead to com-
plete healing. Moreover, therapies based on promoting 
in situ neuronal generation may offer more healing 
potential than strategies based on modulators of neu-
rotransmitters such as memantine and d- cycloserine. 
NSPC transplantation106 (that is, neural stem cell 
therapy) into specific brain areas involved in addic-
tive behaviours could hypothetically have the same 
benefits as neurogenesis- based approaches. Indeed, 
in contrast to ESCs, the risk of tumour formation 
with NSPCs is reduced because NSPC differentiation 
is restricted to the neuronal and glial lineages130. The 
only limitation of both the neurogenesis- based strategy 
and NSPC transplantation is the possibility of propa-
gation of the altered brain chemistry due to chronic 
opioid use from host to new cells or grafts such as in 
the case of Parkinson disease treatment130. Overall, cell 
replacement therapy has the potential to be the future 
of addiction therapy practice. Additionally, a holis-
tic approach integrating personalized counselling, 
nutritional support, lifestyle modifications and/or 
mindfulness- based interventions131 is required to 
avoid psychological and environmental causes and risk 
factors for relapse.
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